Business
£2m contract for a pivotal cancer therapy trial
£2m contract for a pivotal cancer therapy trial.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n\nCambridge Cognition Holdings Plc\n \n(\"Cambridge Cognition\" or the \"Company\")\n \nCambridge Cognition wins £2 million contract for a pivotal cancer therapy trial\n \nCambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce it has won a £2 million contract for a pivotal cancer therapy trial. The Company will provide its proprietary cognitive assessments (CANTAB®) as an exploratory endpoint with revenue from the contract expected to be recognised over the next five years. \nRegulatory approvals for oncology drugs have almost tripled over the last 10 years (16 approvals in 2013 to 43 approvals in 2022)1. With a growing number of therapeutics available, pharmaceutical companies are now investing heavily in differentiating their new drugs and are particularly focused on limiting long-term side effects, such as cognitive impairment, which impacts 30% of patients following chemotherapy2.\nCognitive decline associated with cancer most notably affects attention, memory, and executive function. CANTAB® offers the sensitivity and specificity to measure these distinct cognitive processes. Recognising this, CANTAB® has been selected as an exploratory endpoint in this pivotal oncology trial. Cambridge Cognition secured this contract because not only does it offer well-validated, proprietary assessments, but a delivery platform with a track record of successful, global deployment. Supported by the Company's experienced clinical project management team, CANTAB® will be deployed in 9 countries and in 11 languages to accurately assess cognition across 70 trial sites.\nCommenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:\n\"Advances in cancer treatment have led to increased consideration for limiting the side-effects that impact patients' quality of life. Reducing cognitive impairment could have a major impact on patients' lives. We are pleased to be working with a major pharmaceutical company to support their development programme. With significant investment being made in cancer trials by the world's leading pharmaceutical companies, we expect that this could become a considerable growth area for Cambridge Cognition in the future.\"\nThis announcement contains inside information for the purposes of Article 7 of Regula...